ImmuCell (ICCC) director awarded 10,000 stock options at $5.49 strike

Rhea-AI Filing Summary

ImmuCell Corp. director Paul R. Wainman received a grant of stock options as part of his compensation. On April 16, 2025, he was awarded non-qualified options to acquire 10,000 shares of ImmuCell common stock at an exercise price of $5.49 per share.

The options become exercisable on April 16, 2028 and expire on April 16, 2030. Following this grant, Wainman holds 10,000 stock options directly, and this filing does not show any sales or open-market purchases of common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Wainman Paul R

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Non Qualified Stock Options (Right to buy)	10,000	$0.00	--

Holdings After Transaction: Non Qualified Stock Options (Right to buy) — 10,000 shares (Direct)

Footnotes (1)

Key Figures

Options granted: 10,000 options Exercise price: $5.49 per share Total options after grant: 10,000 options +2 more

5 metrics

Options granted 10,000 options Non-qualified stock options granted on April 16, 2025

Exercise price $5.49 per share Exercise price for 10,000 options

Total options after grant 10,000 options Holdings following reported transaction

Exercise date April 16, 2028 Date options become exercisable

Expiration date April 16, 2030 Options expiration

Key Terms

Non Qualified Stock Options, grant/award acquisition, exercise price, expiration date

4 terms

Non Qualified Stock Options financial

"Non Qualified Stock Options (Right to buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

exercise price financial

"conversion_or_exercise_price: 5.4900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2030-04-16T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wainman Paul R

(Last) (First) (Middle)

C/O IMMUCELL CORPORATION

56 EVERGREEN DRIVE

(Street)

PORTLAND MAINE 04103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IMMUCELL CORP /DE/ [ ICCC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/16/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non Qualified Stock Options (Right to buy)	$5.49	04/16/2025		A		10,000		04/16/2028	04/16/2030	Common Stock	10,000	$0	10,000	D

Explanation of Responses:

Remarks:

The options were granted by the Issuer to compensate directors for services on the Issuer's board of directors.

	/s/ Timothy C. Fiori Attorney-in-Fact	04/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did ImmuCell (ICCC) report for Paul R. Wainman?

ImmuCell reported that director Paul R. Wainman received a grant of 10,000 non-qualified stock options. These options give him the right to buy ImmuCell common stock at a fixed price as part of his equity-based compensation.

How many ImmuCell (ICCC) stock options were granted to Paul R. Wainman?

Paul R. Wainman was granted 10,000 non-qualified stock options. Each option represents the right to purchase one share of ImmuCell common stock, aligning his incentives with shareholders through potential future share ownership.

What is the exercise price of Paul R. Wainman’s ImmuCell (ICCC) stock options?

The exercise price of Paul R. Wainman’s stock options is $5.49 per share. This means he can buy ImmuCell common stock at $5.49 when the options are exercisable, regardless of the market price at that time.

When can Paul R. Wainman exercise his ImmuCell (ICCC) stock options?

Paul R. Wainman’s options become exercisable on April 16, 2028. After that date, he may choose to exercise the options before they expire, subject to the plan’s terms and any company or regulatory trading restrictions.

When do Paul R. Wainman’s ImmuCell (ICCC) stock options expire?

Paul R. Wainman’s stock options expire on April 16, 2030. If he has not exercised them by that date, the options will lapse and no longer provide the right to purchase ImmuCell common shares at the $5.49 exercise price.

Did Paul R. Wainman buy or sell any ImmuCell (ICCC) common shares in this Form 4?

This Form 4 shows only a grant of 10,000 non-qualified stock options to Paul R. Wainman. It does not report any open-market purchases or sales of ImmuCell common stock by him on the transaction date.